Skip to content
Head to head

Structure Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: GPCR · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

GPCR -56.9%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
GPCRVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price16.13515.02
Change today-5.78%-1.08%
1-year return-53.0%+22.0%
Market cap$1.15B$130.58B
52-week range16.06 – 94.90412.27 – 568.67
Valuation
P/E (TTM)-4.1433.14
P/E percentile, own 5-yr range99th99th
P/B0.956.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.4015.32
Net profit (TTM)$-171.82M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-277.28M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership105.7%96.8%
Insider activity (12mo)28 buy / 22 sell28 buy / 22 sell
Short interest (% of float)8.3%1.9%
Analyst consensus100% buy (10)95% buy / 5% hold (21)
Analyst price target$104 (+543%)$624 (+21%)
StockVane view
StockVane Quant RatingE (5)C (68)
Company
Employees2206,400
Founded20161989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.